Washington, Nov 14 (ANI): Preclinical studies have found that combination of the investigational agents REGN910 and aflibercept yield statistically significant improvements in anti-tumour effects in animal models compared with either agent alone.
"These preclinical findings suggest that combining REGN910 (SAR307746) and aflibercept in the clinic could be an attractive approach for future clinical research," said Alshad S. Lalani, Ph.D., director of strategic oncology development at Regeneron Pharmaceuticals Inc. in Tarrytown, N.Y.
"The rationale is that inhibition of tumour angiogenesis by combining antiangiogenesis treatments could translate into more potent and durable anti-tumour responses than those observed with single-agent therapy," Lalani stated.
In this preclinical mouse study, researchers from Regeneron and BC Cancer Agency in Vancouver, British Columbia, Canada, monitored how REGN910 and aflibercept blocked vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2), which are critical growth factors for tumour angiogenesis, or blood vessel formation.
REGN910 is a fully human monoclonal antibody discovered using Regeneron VelocImmune antibody technology that binds and inhibits Ang2. Aflibercept is a fully human fusion protein that binds all forms of VEGF-A, as well as VEGF-B and placental growth factor.
REGN910 and aflibercept are being developed by Regeneron and Sanofi.
"When used alone in animal studies, both REGN910 and aflibercept blocked tumour angiogenesis and growth; however, the combination of the two led to increased tumour hypoxia and consequently to the death of a large percentage of the tumour cells," Lalani said.
The study was presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011. (ANI)
null
|
|
Read More: Cancer
Comments:
